CVS, Walgreens Report 200,000 Medicare $50 Obesity Drug Prescriptions
CVS and Walgreens each say they have filled about 100,000 Medicare "Bridge" prescriptions for $50-a-month obesity drugs, roughly 200,000 total, signaling strong early uptake of the pilot program.[1]
Walmart says Bridge prescriptions are rising and have been processed at more than 5,000 of its pharmacies.[1] The Bridge runs through December 31, 2027, charges a $50 patient copay, and covers beneficiaries with obesity plus qualifying conditions while excluding those with sleep apnea or Type 2 diabetes.[1]
On December 19, 2025, the Centers for Medicare & Medicaid Services announced the Medicare GLP-1 Bridge demonstration and a companion BALANCE Model to test expanded access to GLP-1 drugs for weight loss. The Bridge launched July 1, 2026 after a November 2025 deal with Eli Lilly and Novo Nordisk that cut net prices to $245 per month and allowed CMS to operate the pilot outside ordinary Part D rules using Section 402 authority.
About 70 million people were enrolled in Medicare as of March 2026, and list prices for leading GLP-1 weight-loss drugs still exceed $1,000 a month in 2026 — Wegovy tops $1,300 and Zepbound exceeds $1,000 — underscoring why a $50 copay could matter to beneficiaries.
The mainstream summary highlights the initial uptake of the Medicare Bridge program but fails to mention the broader context of Medicare's statutory restrictions on weight-loss drug coverage. While the summary notes the program's $50 copay, it does not explain that current law prohibits Medicare from covering weight-loss drugs, which has driven CMS to utilize Section 402 demonstration authority for this pilot. This workaround is significant given that analyses suggest there are approximately 3.8 million eligible Part D enrollees who could benefit from the program, indicating a much larger potential impact than the initial prescription numbers suggest.
Additionally, the summary does not address the stark contrast between the $50 copay and the list prices of leading GLP-1 drugs, which exceed $1,000 per month. This pricing disparity underscores the importance of the Bridge program for beneficiaries and highlights the ongoing challenges posed by the obesity epidemic in the U.S., as noted in studies linking food energy supply and ultra-processed foods to rising obesity rates. Such insights provide a more nuanced understanding of the implications of this pilot program and its potential to address a significant public health issue.[2][3][4]26567-3/fulltext)
Show source details & analysis (1 source)
📊 Relevant Data
Approximately 70 million people were enrolled in Medicare as of March 2026.
CMS posts March 2026 Medicare data; 70.2 million total — ACA Signups
The list price of Wegovy exceeds $1,300 per month and Zepbound exceeds $1,000 per month without insurance coverage or manufacturer discounts.
Wegovy Costs, Insurance & Savings Tips — Forbes Health
📌 Key Facts
- Medicare's Bridge pilot program, which started in July 2026, lets eligible beneficiaries obtain certain obesity drugs for $50 per month despite a statutory bar on Medicare covering weight loss drugs.
- As of mid to late August 2026, CVS and Walgreens each report having filled around 100,000 Bridge prescriptions, while Walmart says Bridge prescriptions are rising and have been processed at more than 5,000 of its pharmacies.
- The Bridge program runs through the end of 2027, covers patients with obesity plus specified conditions such as hard-to-control hypertension, and excludes beneficiaries with sleep apnea or Type 2 diabetes, who are expected to access GLP-1s under existing Part D coverage.
📰 Source Timeline (1)
Follow how coverage of this story developed over time